LLY - ELI LILLY & Co
873.68
-3.210 -0.367%
Share volume: 3,940,432
Last Updated: Fri 21 Feb 2025 10:00:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.42%
PREVIOUS CLOSE
CHG
CHG%
$876.89
0.56
0.00%
Fundamental analysis
79%
Profitability
95%
Dept financing
33%
Liquidity
52%
Performance
80%
Performance
5 Days
1.92%
1 Month
13.97%
3 Months
15.72%
6 Months
-8.30%
1 Year
13.41%
2 Year
166.76%
Key data
Stock price
$873.68
DAY RANGE
$873.43 - $894.40
52 WEEK RANGE
$711.40 - $972.53
52 WEEK CHANGE
$13.24
DIVIDEND
$1.50
EX-DIVIDEND DATE
02/14/2025
NEXT EARNINGS DATE
N/A
Company detail
CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax
Recent news